Overview

The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation

Status:
Unknown status
Trial end date:
2021-09-30
Target enrollment:
0
Participant gender:
All
Summary
No randomized head-to-head comparison between the individual Non-vitamin K Antagonist Oral Anticoagulants (NOAC) exists. The DANNOAC-AF study is a nationwide cluster randomized cross-over study comparing efficacy and safety of the four NOACs, edoxaban, apixaban, rivaroxaban and dabigatran for oral anticoagulation in non-valvular atrial fibrillation across Danish hospitals and cardiology clinics.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Danish Heart Foundation
Collaborator:
Danish Society of Cardiology
Treatments:
Anticoagulants
Apixaban
Dabigatran
Edoxaban
Rivaroxaban
Criteria
Inclusion Criteria:

- A diagnosis of atrial fibrillation in outpatient clinic or as discharge diagnosis
after hospitalization.

- A claimed prescription of a NOAC from a Danish pharmacy within 14 days of discharge or
outpatient clinic visit.

Exclusion Criteria:

- A prescription of a NOAC within 90 days prior to hospitalization or outpatient clinic
visit for AF.

- Presence of a mechanic cardiac valve prosthesis.

- Patients with NOAC preference apart from preference consistent with current cluster
randomized NOAC.

- Other contraindications mentioned in the "Summary of Product Characteristics" for the
respective NOAC.